Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05853575 |
|
Recruitment Status :
Recruiting
First Posted : May 10, 2023
Last Update Posted : May 8, 2024
|
Sponsor:
Mirati Therapeutics Inc.
Information provided by (Responsible Party):
Mirati Therapeutics Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 2025 |
| Estimated Study Completion Date : | September 2025 |